Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1F | O60840 | 10/20 | 0.46 |
| ▸ | CACNA1D | Q01668 | 10/20 | 0.46 |
| ▸ | CACNA1S | Q13698 | 10/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 10/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.46 |
| ▸ | GUSB | P08236 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5568260 | 0.94 | CACNA1H (0.48) | CACNA1FCACNA1DCACNA1SCACNA1CCACNA1H | |
| SCHEMBL5567923 | 0.91 | CACNA1H (0.49) | CACNA1FCACNA1DCACNA1SCACNA1CCACNA1H | |
| SCHEMBL5567327 | 0.90 | CACNA1H (0.46) | CACNA1FCACNA1DCACNA1SCACNA1CCACNA1H | |
| SCHEMBL5567034 | 0.90 | CACNA1H (0.46) | CACNA1FCACNA1DCACNA1SCACNA1CCACNA1H | |
| SCHEMBL5568432 | 0.90 | CACNA1H (0.47) | CACNA1FCACNA1DCACNA1SCACNA1CCACNA1H | |
| SCHEMBL5563158 | 0.88 | CACNA1H (0.44) | CACNA1FCACNA1DCACNA1SCACNA1CCACNA1H | |
| SCHEMBL5568170 | 0.88 | CACNA1H (0.46) | CACNA1FCACNA1DCACNA1SCACNA1CCACNA1H | |
| SCHEMBL5567957 | 0.88 | CACNA1H (0.46) | CACNA1FCACNA1DCACNA1SCACNA1CCACNA1H | |
| SCHEMBL5567165 | 0.88 | CACNA1H (0.44) | CACNA1FCACNA1DCACNA1SCACNA1CCACNA1H | |
| SCHEMBL5567236 | 0.88 | CACNA1H (0.47) | CACNA1FCACNA1DCACNA1SCACNA1CCACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166603-B2 | Dihydropyrimidone inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | claimed |
| US-20050043339-A1 | Dihydropyrimidone inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB COMPANY | 2005-02-24 | — | — | US | claimed |
| US-7166603-B2 | Dihydropyrimidone inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20050043339-A1 | Dihydropyrimidone inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB COMPANY | 2005-02-24 | — | — | US | disclosed |
| WO-2005009392-A2 | DIHYDROPYRIMIDONE INHIBITORS OF CALCIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043339-A1 | Dihydropyrimidone inhibitors of calcium channel function | CACNA1E, CACNA1C, CACNA1S | CACNA1F 6/4885CACNA1D 4/4885CACNA1S 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.